Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer

Oncology Letters

Volumn 14, Issue 2, 2017, Pages 1993-2000

  Lu, Xueying ^a,b   Li, Yanhong ^c   Li, Xiaobo ^a,b   Aisa, Haji Akber ^a,b  

^a XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY   (China)

^b State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization   (China)

^c XINJIANG NORMAL UNIVERSITY   (China)

Author keywords

CXCL16; DUSPs; Gastric carcinoma; Luteolin; MAPK; PI3K

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA CHEMOKINE; CASPASE 3; CASPASE 9; CXCL16 CHEMOKINE; CYTOCHROME C; DIMETHYL SULFOXIDE; DUAL SPECIFICITY PHOSPHATASE; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

EID: 85021771700     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6380     Document Type: Article

References (74)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11. International Agency for Research on Cancer, Lyon, France, 2013.
2. Rahman R, Asombang AW and Ibdah JA: Characteristics of gastric cancer in Asia. World J Gastroenterol 20: 4483-4490, 2014.
3. Menges M and Hoehler T: Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 135: 29-38, 2009.
4. Green D, Ponce de Leon S, Leon-Rodriguez E and Sosa-Sanchez R: Adenocarcinoma of the stomach: Univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol 25: 84-89, 2002.
5. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10 (Suppl 3): S49-S58, 2005.
6. Hejna M, Wöhrer S, Schmidinger M and Raderer M: Postoperative chemotherapy for gastric cancer. Oncologist 11: 136-145, 2006.
7. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, et al: Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100: 388-398, 2008.
8. Yan Y, Wang LF and Wang RF: Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World J Gastroenterol 21: 9717-9726, 2015.
9. Mendoza MC, Er EE and BlenisJ: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36: 320-328, 2011.
10. Trisciuoglio D, Iervolino A, Zupi G and Del Bufalo D: Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 16: 4153-4162, 2005.
11. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC: Activated mitogen- activated kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753, 2002.
12. Kress TR, Raabe T and Feller SM: High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells. Cell Commun Signal 8: 1, 2010.
13. Uzgare AR, Kaplan PJ and Greenberg NM: Differential expression and/or activation of P38MAPK, ERK1/2, and JNK during the initiation and progression of prostate cancer. Prostate 55: 128-139, 2003.
14. Lin HL, Yang MH, Wu CW, Chen PM, Yang YP, Chu YR, Kao CL, Ku HH, Lo JF, Liou JP, et al: 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway- mediated metastasis of gastric cancer. Int J Cancer 121: 2547-2555, 2007.
15. An JY, Kim KM, Choi MG, Noh JH, Sohn TS, Bae JM and Kim S: Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126: 2904-2913, 2010.
16. Miean KH and Mohamed S: Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 49: 3106-3112, 2001.
17. Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, Hashimoto T and Mizuno M: Intestinal anti-inflammatory activity of luteolin: Role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells. Biofactors 39: 522-533, 2013.
18. Ashokkumar P and Sudhandiran P: Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother 62: 590-597, 2008.
19. Ashokkumar P and Sudhandiran G: Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs 29: 273-284, 2011.
20. Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, Tabara H, Inoue T, Hagiyama M, Ito A, et al: Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One 9: e100124, 2014.
21. Wu B, Zhang Q, Shen WM and Zhu J: Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol Cell Biochem 313: 125-132, 2008.
22. Wang HY, Quan K, Jiang YL, Wu JG and Tang XW: Effect of Luteolin and its combination with chemotherapeutic drugs on cytotoxicity of cancer cells. Zhejiang Da Xue Xue Bao Yi Xue Ban 39: 30-36, 2010 (In Chinese).
23. Ding S, Hu A, Hu Y, Ma J, Weng P and Dai J: Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest. Tumour Biol 35: 3053-3060, 2014.
24. Shi RX, Ong CN and Shen HM: Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Oncogene 23: 7712-7721, 2004.
25. Manju V and Nalini N: Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis. Cell Biochem Funct 25: 189-194, 2007.
26. Samy RP, Gopalakrishnakone P and Ignacimuthu S: Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a) anthracene-induced mammary tumors in rats. Chem Biol Interact 164: 1-14, 2006.
27. Amin AR, Kucuk O, Khuri FR and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27: 2712-2725, 2009.
28. Pandurangan AK, Dharmalingam P, Ananda Sadagopan SK and Ganapasam S: Effect of luteolin on the levels of glycoproteins during azoxymethane-induced colon carcinogenesis in mice. Asian Pac J Cancer Prev 13: 1569-1573, 2012.
29. Sagawa H, Naiki-Ito A, Kato H, Naiki T, Yamashita Y, Suzuki S, Sato S, Shiomi K, Kato A, Kuno T, et al: Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis 36: 1539-1549, 2015.
30. Kasala ER, Bodduluru LN, Barua CC and Gogoi R: Antioxidant and antitumor efficacy of Luteolin, a dietary flavone on benzo(a) pyrene-induced experimental lung carcinogenesis. Biomed Pharmacother 82: 568-577, 2016.
31. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
32. Lu Xueying, Li Yanhong, Xiao Xiangwen, Haji Akber Aisa and Li Xiaobo: Study on inhibition of luteolin on proliferation of human gastric cancer cell line BGC-823. Mod J Integr Tradit Chinese Western Med 3: 246-249, 2012.
33. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
34. Thornberry NA and Lazebnik Y: Caspases: Enemies within. Science 281: 1312-1316, 1998.
35. Pradelli LA, Bénéteau M and Ricci JE: Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci 67: 1589-1597, 2010.
36. Otera H and Mihara K: Mitochondrial dynamics: Functional link with apoptosis. Int J Cell Biol 2012: 821676, 2012.
37. Kumar A, Ganini D and Mason RP: Role of cytochrome c in α-synuclein radical formation: Implications of α-synuclein in neuronal death in Maneb- and paraquat-induced model of Parkinson's disease. Mol Neurodegener 11: 70, 2016.
38. Lopez-Cruzan M, Sharma R, Tiwari M, Karbach S, Holstein D, Martin CR, Lechleiter JD and Herman B: Caspase-2 resides in the mitochondria and mediates apoptosis directly from the mitochondrial compartment. Cell Death Discov 2: pii: 16005, 2016.
39. Rong Y and Distelhorst CW: Bcl-2 protein family members: Versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol 70: 73-91, 2008.
40. Li C, Wu X, Sun R, Zhao P, Liu F and Zhang C: Croton tiglium extract induces apoptosis via Bax/Bcl-2 pathways in human lung cancer A549 cells. Asian Pac J Cancer Prev 17: 4893-4898, 2016.
41. Zhang S, Qin F, Yang L, Xian J, Zou Q, Jin H, Wang L and Zhang L: Nucleophosmin mutations induce chemosensitivity in THP-1 leukemia cells by suppressing NF-κB Activity and regulating Bax/Bcl-2 expression. J Cancer 7: 2270-2279, 2016.
42. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, et al: The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153: 840-854, 2013.
43. Sapey E, Greenwood H, Walton G, Mann E, Love A, Aaronson N, Insall RH, Stockley RA and Lord JM: Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: Toward targeted treatments for immunosenescence. Blood 123: 239-248, 2014.
44. Patterson KI, Brummer T, O'Brien PM and Daly RJ: Dual-specificity phosphatases: Critical regulators with diverse cellular targets. Biochem J 418: 475-489, 2009.
45. Theodosiou A and Ashworth A. MAP kinase phosphatases. Genome Biol 3: REVIEWS3009, 2002.
46. Camps M, Nichols A and Arkinstall S: Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB J 14: 6-16, 2000.
47. Keyse SM: Protein phosphatases and the regulation of mitogenactivated protein kinase signaling. Curr Opin Cell Biol 12: 186-192, 2000.
48. Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, et al: Loss of somatostatin receptor subtype 2 promotes growth of KRAS-induced pancreatic tumors in mice by activating PI3K signaling and overexpression of CXCL16. Gastroenterology 148: 1452-1465, 2015.
49. Chiu FL and Lin JK: Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68: 61-71, 2008.
50. Lim DY, Jeong Y, Tyner AL and Park JH: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 292: G66-G75, 2007.
51. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
52. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004.
53. Chang L and Karin M: Mammalian MAP kinas signaling cascades. Nature 410: 37-40, 2001.
54. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK Pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
55. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681, 2005.
56. Huang CY and Tan TH: DUSPs, to MAP kinases and beyond. Cell Biosci 2: 24, 2012.
57. Jeffrey KL, Camps M, Rommel C and Mackay CR: Targeting dual-specificity phosphatases: Manipulating MAP kinase signaling and immune responses. Nat Rev Drug Discov 6: 391-403, 2007.
58. Nunes-Xavier C, Romá-Mateo C, Ríos P, Tárrega C, Cejudo-Marín R, Tabernero L and Pulido R: Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 11: 109-132, 2011.
59. Duronio V: The life of a cell: Apoptosis regulation by the PI3K/PKB pathway. Biochem J 415: 333-344, 2008.
60. Guo C, Yang M, Jing L, Wang J, Yu Y, Li Y, Duan J, Zhou X, Li Y and Sun Z: Amorphous silica nanoparticles trigger vascular endothelial cell injury through apoptosis and autophagy via reactive oxygen species-mediated MAPK/Bcl-2 and PI3K/Akt/mTOR signaling. Int J Nanomedicine 11: 5257-5276, 2016.
61. Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL and Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279: 21085-21095, 2004.
62. Yao R and Cooper GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267: 2003-2006, 1995.
63. Scheid MP, Lauener RW and Duronio V: Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: Phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J 312: 159-162, 1995.
64. Pande M, Bondy ML, Do KA, Sahin AA, Ying J, Mills GB, Thompson PA and Brewster AM: Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 147: 381-387, 2014.
65. Luster AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445, 1998.
66. Struyf S, Proost P and Van Damme J: Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 81: 1-44, 2003.
67. Guerreiro R, Santos-Costa Q and Azevedo-Pereira JM: The chemokines and their receptors: Characteristics and physiological functions. Acta Med Port 24 (Suppl 4): S967-S976, 2011 (In Portuguese).
68. Xing YN, Xu XY, Nie XC, Yang X, Yu M, Xu HM, Liu YP, Takano Y and Zheng HC: Role and clinicopath- ologic significance of CXC chemokine ligand 16 and chemokine (C-X-C motif) receptor 6 expression in gastric carcinomas. Hum Pathol 43: 2299-2307, 2012.
69. Wang J, Lu Y, Wang J, Koch AE, Zhang J and Taichman RS: CXCR6 induces prostate cancer progression by the AKT/Mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367-10376, 2008.
70. Chandrasekar B, Bysani S and Mummidi S: CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 279: 3188-3196, 2004.
71. Deng L, Chen N, Li Y, Zheng H and Lei Q: CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta 1806: 42-49, 2010.
72. Singh R, Kapur N, Mir H, Singh N, Lillard JW Jr and Singh S: CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering. Oncotarget 7: 7343-7353, 2016.
73. Hu ZB, Chen Y, Gong YX, Gao M, Zhang Y, Wang GH, Tang RN, Liu H, Liu BC and Ma KL: Activation of the CXCL16/CXCR6 pathway by inflammation contributes to atherosclerosis in patients with End-stage renal disease. Int J Med Sci 13: 858-867, 2016.
74. Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, et al: Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: Combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer 16: 916, 2016.